Harnessing data for AD

How CEOi, Optum Labs plan to use big data to help move needle in AD

A new initiative from the Global CEO Initiative on Alzheimer's Disease and Optum Labs aims to harness big data sets and analysis tools to better identify patients at risk for developing Alzheimer's disease. The partners expect AD stakeholders will use the data and tools to tailor patient care and save the healthcare system money.

A not-for-profit industry coalition focused on AD research, the Global CEO Initiative on Alzheimer's Disease (CEOi) is leading the Big Data Research Initiative to Fight Alzheimer's Disease, which was launched last month to provide resources to enable industry, academia and government agencies to use big data to develop a better understanding of who will develop AD, and when; how quickly a person's AD will progress; and how best to deliver care.

"You can see a wide variety of potentially quite interesting things happening to people on the path to Alzheimer's and people not on the path to Alzheimer's" by looking through claims data, electronic health records and consumer data, said George Vradenburg, founder and chairman of not-for-profit advocacy group USAgainstAlzheimer's. Vradenburg and USAgainstAlzheimer's convened CEOi.

CEOi's effort is the latest big data initiative looking to tackle AD. The latest results from another initiative, NIH's Accelerating Medicine Partnership

Read the full 2043 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE